e-Drug3D
1605
VILANTEROL
INN
VILANTEROL
cas 503068-34-6
CLASS
RESPIRATORY
LONG-ACTING BETA2-ADRENERGIC AGONIST (LABA)
BRONCHIAL SMOOTH MUSCLE
TREATMENT OF AIRFLOW OBSTRUCTION AND FOR REDUCING EXACERBATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
ROUTE (list)
INHALATION
PK parameters
F 27.3 PERCENT
VD 165 LITER
Cl 5.3 LITER / HOUR (EQN)
PPB 93.9 PERCENT
t1/2 21.3 HOUR
Solubility
PRATICALLY INSOLUBLE IN WATER
TARGET BETA2-ADRENERGIC RECEPTOR
Beta-2 adrenergic receptor UNIPROT P07550 ADRB2
Formula:
C24H33Cl2NO5
Calculated chemical properties:
MW 486.41
NB_atoms 32
XLogP 4.61
PSA 95.874
NB_HD 4
NB_HA 6
fsp3 0.50
Lipinski(0=no;1=yes) 1
NB_atoms 32
XLogP 4.61
PSA 95.874
NB_HD 4
NB_HA 6
fsp3 0.50
Lipinski(0=no;1=yes) 1
FDA
NDA 204275 (label) INN (FLUTICASONE FUROATE ; VILANTEROL TRIFENATATE) BREO ELLIPTA (GLAXO GRP LTD) APPROVAL= AP YEAR= 2013 NEWMOLECULARENTITY
NDA 203975 (label) INN (UMECLIDINIUM BROMIDE ; VILANTEROL TRIFENATATE) ANORO ELLIPTA (GLAXOSMITHKLINE) APPROVAL= AP YEAR= 2013
NDA 209482 (label) INN (FLUTICASONE FUROATE ; UMECLIDINIUM BROMIDE ; VILANTEROL TRIFENATATE) TRELEGY ELLIPTA (GLAXOSMITHKLINE) APPROVAL= AP YEAR= 2017
NDA 204275 (label) INN (FLUTICASONE FUROATE ; VILANTEROL TRIFENATATE) BREO ELLIPTA (GLAXO GRP LTD) APPROVAL= AP YEAR= 2013 NEWMOLECULARENTITY
NDA 203975 (label) INN (UMECLIDINIUM BROMIDE ; VILANTEROL TRIFENATATE) ANORO ELLIPTA (GLAXOSMITHKLINE) APPROVAL= AP YEAR= 2013
NDA 209482 (label) INN (FLUTICASONE FUROATE ; UMECLIDINIUM BROMIDE ; VILANTEROL TRIFENATATE) TRELEGY ELLIPTA (GLAXOSMITHKLINE) APPROVAL= AP YEAR= 2017